Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 50   

Articles published

ALKS 45.42 -0.49 (-1.07%)
price chart
Is Alkermes plc Stock Undervalued?
In simple terms, what Alkermes plc (NASDAQ: ALKS ) is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent ...
Alkermes plc (ALKS) Receives Notice of Allowance from USPTO Covering Four ...
Alkermes plc (Nasdaq: ALKS) announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes' pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole ...
Insider Selling: Michael J. Landine Unloads 7000 Shares of Alkermes Plc ...  Intercooler
Alkermes Announces Notices of Allowance for US Patents for Four CNS Pipeline ...  MarketWatch
Related articles »  
Alkermes Plc's Neutral Rating Reaffirmed at Zacks (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS)'s stock had its �neutral� rating reiterated by Zacks in a report released on Friday.
Alkermes Plc Receives Consensus Rating of �Buy� from Analysts (NASDAQ:ALKS)  Intercooler
Insider Selling: James M. Frates Sells 7000 Shares of Alkermes Plc Stock (ALKS)  Watch List News (press release)
Related articles »  
Insider Selling: James M. Frates Sells 8000 Shares of Alkermes Plc Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 8,000 shares of Alkermes Plc stock on the open market in a transaction that occurred on Wednesday, July 16th.
Drug Delivery: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Alkermes Plc ...  Crazy Joys
Related articles »  
Drug Delivery: Valeant Pharmaceuticals International (NYSE:VRX), Alkermes plc ...
Following the transaction, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $2,056,463.
Alkermes Plc Given Average Recommendation of �Buy� by Brokerages ...
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) has received a consensus recommendation of �Buy� from the nine analysts that are covering the company, Analyst Ratings.
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for ...  Wall Street Journal
Related articles »  
Alkermes plc (ALKS) Jumps: Stock Rises 5.7%
Alkermes plc (ALKS - Analyst Report) was a big mover last session, as the company saw its shares rise by almost 6% on the day.
Insider Selling: Alkermes Plc CEO Sells 50000 Shares of Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 50,000 shares of Alkermes Plc stock in a transaction dated Wednesday, July 2nd.
Insider Selling: Richard F. Pops Unloads 50000 Shares of Alkermes Plc Stock ...  Mideast Time
Related articles »  
Alkermes plc (ALKS) Jumps: Stock Rises 5.7% - Tale of the Tape
Alkermes plc ( ALKS ) was a big mover last session, as the company saw its shares rise by almost 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Insider Selling: Elliot Ehrich Sells 17282 Shares of Alkermes Plc Stock (ALKS)  Ticker Report
Related articles »  
Alkermes Plc COO Sells $743840 in Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) COO Gordon G. Pugh unloaded 16,000 shares of the stock in a transaction dated Tuesday, July 1st.